Moderna Inc.
Moderna Reports Q3 2024 Financial Results and Business Updates
Summary
Moderna, Inc. reported financial results for the third quarter of 2024, with total revenues of $1.9 billion and a net income of $13 million. The company's updated COVID-19 vaccine contributed significantly to the revenue, with sales of $1.8 billion, while the RSV vaccine generated $10 million in sales. Moderna also shared positive updates on its late-stage pipeline, including progress on its next-generation COVID-19 and RSV vaccines. Additionally, the company announced expansions in its Executive Committee.
Profitelligence Alerts
Get alerts for MRNA
Be first to know when Moderna Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Official SEC Documents
Advertisement